News from Anthera Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

25 Jan, 2013, 08:57 ET Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 60,606,061 shares of its...


24 Jan, 2013, 16:01 ET Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten...


28 Nov, 2012, 08:00 ET Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


20 Nov, 2012, 17:00 ET Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


13 Nov, 2012, 17:17 ET Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


01 Nov, 2012, 08:00 ET Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


24 Oct, 2012, 17:00 ET Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended September 30, 2012....


18 Oct, 2012, 17:00 ET Anthera Announces Third Quarter 2012 Financial Report and Conference Call

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


17 Sep, 2012, 08:00 ET Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


07 Aug, 2012, 16:15 ET Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2012....


01 Aug, 2012, 14:00 ET Anthera to Report Second Quarter 2012 Financial Results

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


24 Jul, 2012, 16:15 ET Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of...


19 Jul, 2012, 09:16 ET Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 33 million shares of its...


18 Jul, 2012, 16:22 ET Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it intends to offer and sell shares of its common stock in an...


16 Jul, 2012, 13:26 ET Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


09 Jul, 2012, 17:02 ET Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


27 Jun, 2012, 17:40 ET Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


03 May, 2012, 17:00 ET Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update

 Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2012....


27 Apr, 2012, 12:00 ET Anthera Announces First Quarter 2012 Financial Report and Conference Call

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


25 Apr, 2012, 14:29 ET Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...